CVS Health Corporation $CVS Stock Position Lessened by Dodge & Cox

Dodge & Cox decreased its position in shares of CVS Health Corporation (NYSE:CVS) by 0.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,176,586 shares of the pharmacy operator’s stock after selling 112,180 shares during the period. CVS Health accounts for 3.0% of Dodge & Cox’s holdings, making the stock its 4th biggest position. Dodge & Cox owned 0.06% of CVS Health worth $5,516,783,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of CVS Health by 1.7% during the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares in the last quarter. Capital World Investors boosted its position in shares of CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after purchasing an additional 1,419,575 shares in the last quarter. State Street Corp increased its position in CVS Health by 1.4% during the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after buying an additional 800,414 shares in the last quarter. Capital International Investors increased its position in CVS Health by 1.1% during the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after buying an additional 302,499 shares in the last quarter. Finally, Invesco Ltd. raised its stake in CVS Health by 3.2% in the third quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research analyst reports. Sanford C. Bernstein upgraded CVS Health from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $91.00 to $94.00 in a research note on Thursday. Mizuho lifted their target price on shares of CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Argus cut their price target on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. Robert W. Baird raised their price target on shares of CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Finally, Morgan Stanley lifted their price objective on shares of CVS Health from $89.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $95.05.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” with a $94 price target, signaling upward analyst momentum and providing a clear catalyst for investor sentiment. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced a new AI-powered health platform, which could boost growth prospects for care management, digital engagement and margin improvement if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause accredited, strengthening its clinical services and retail clinic positioning in women’s health — a niche revenue/traffic driver over time. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are revising fair‑value estimates modestly (one update moved fair value ~US$94→US$96), reflecting balanced views: upside from Medicare Advantage exposure but uncertainty on managed‑care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Competitive dynamics: a North Carolina health plan is triggering a bidding fight for 2028 Aetna/CVS contracts — potential upside if CVS wins, but outcome uncertain. N.C. Health Plan Sparks 2028 Bidding War Over Aetna And CVS Contracts
• Neutral Sentiment: Market reaction since earnings: commentary and data pieces note the stock has moved modestly since last quarter; investors are parsing guidance and EPS trajectory for cues. Why Is CVS Health (CVS) Down 1.7% Since Last Earnings Report?
• Negative Sentiment: Aetna, a CVS subsidiary, agreed to a $117.7M DOJ settlement over alleged inaccurate diagnosis coding in Medicare Advantage — a material legal headline that keeps compliance and MA reimbursement risk on investors’ radar. Aetna’s US$117.7m Settlement Puts CVS Health Compliance In Focus
• Negative Sentiment: Policy risk: CVS warned it may close 100+ Tennessee pharmacies if proposed PBM legislation passes, highlighting state‑level regulatory risk that could reduce retail footprint and revenues in affected markets. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Price Performance

Shares of NYSE CVS opened at $76.14 on Friday. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15. The business’s 50 day moving average price is $78.17 and its 200 day moving average price is $77.74. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The firm has a market cap of $96.87 billion, a P/E ratio of 55.17, a P/E/G ratio of 0.79 and a beta of 0.49.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s dividend payout ratio is presently 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.